LEUPROLIDE ACETATE

Other

Brand names: Vabrinty, Lupron

Subcutaneous

Mechanism of Action

12.1 Mechanism of Action Leuprolide acetate, a gonadotropin releasing hormone (GnRH) agonist, acts as an inhibitor of gonadotropin secretion when given continuously in therapeutic doses. Animal and human studies indicate that after an initial stimulation, chronic administration of leuprolide acetate results in suppression of testicular and ovarian steroidogenesis. This effect is reversible upon discontinuation of drug therapy.

Indications

See full prescribing information

Contraindications

• 4 CONTRAINDICATIONS Hypersensitivity VABRINTY is contraindicated in patients with hypersensitivity to GnRH
• GnRH agonist analogs or any of the components of VABRINTY. Anaphylactic reactions to synthetic GnRH or GnRH agonist analogs have been reported in the literature. Known hypersensitivity to GnRH
• GnRH agonist analogs or any of the components of VABRINTY ( 4 )

FDA Warnings

5 WARNINGS AND PRECAUTIONS Tumor Flare: Transient increase in serum levels of testosterone during treatment may result in worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment, including bone pain, neuropathy, hematuria, bladder outlet obstruction, ureteral obstruction, or spinal cord compression
Monitor patients at risk closely and manage as appropriate
7 ) Hyperglycemia and diabetes: Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH analogs
2 ) Cardiovascular diseases: Increased risk of myocardial infarction, sudden cardiac death and stroke has been reported in men

Known Side Effects

6 documented side effects by frequency

Fatigue

1-10%

Injection Site Pain

1-10%

Weakness

0.1-1%

Drug Not Working

0.1-1%

Falls

0.1-1%

Joint Pain

0.1-1%

Community Discussions

No community discussions found for LEUPROLIDE ACETATE yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Subcutaneous